2024 年度监事会工作报告 一、2024 年度监事会工作情况 贵阳新天药业股份有限公司 贵阳新天药业股份有限公司（以下简称"公司"）监事会根据《公司法》、 《证券法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律法规及《公司章程》、《监事会议事规则》等公司制度的 规定，本着对全体股东负责的精神，依法独立行使职权，遵守诚信原则，勤勉 履职，认真监督，积极维护公司、股东、员工的权益。现将监事会 2024 年度工 作情况报告如下： 二、监事会对公司 2024 年度有关事项的审核意见 2024 年度，公司监事会认真履行职责，对公司的规范运作、经营管理、财 务状况以及董事、高级管理人员履行职责、公司关联交易、重大资产重组等相 关事项进行全面、系统地监督，监事会对 2024 年度有关事项意见如下： （一）公司规范运作情况 报告期内，公司监事会全体成员认真履行职责，恪尽职守，均按要求出席 了公司监事会会议，对所议议案充分发表了审核意见。同时，公司监事会成员 分别列席和出席了公司董事会会议及股东大会，对公司股东大会、董事会的召 开程序、决议事项、董事会对股东大会决议执行情况、公司高级管理 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-023 一、日常关联交易基本情况 （一）日常关联交易概述 贵阳新天药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日分别 召开了第七届董事会第三十次会议、第七届监事会第二十一次会议，审议通过《关 于 2024 年度日常关联交易执行情况及 2025 年度日常关联交易预计的议案》。为 保证公司（含子公司，下同）正常开展生产经营活动、继续拓展公司及子公司对 外技术服务业务、充分挖掘公司产品的市场潜力提高产品知名度，公司预计 2025 年度将与关联方贵阳臣功新天商业物业管理有限公司（以下简称"臣功商业"） 发生水、电和物业管理等日常关联交易事项；与关联方上海锦竺信息科技有限公 司（以下简称"锦竺科技"）发生软件开发、营销服务等日常关联交易事项；与 关联方广州市优医健康药业连锁有限公司（锦竺科技的全资子公司，以下简称"优 医健康"）发生药品销售等日常关联交易事项；公司全资子公司上海硕方医药科 技有限公司（以下简称"硕方医药"）预计与关联方上海汇伦医药股份有限公司 （以下简称"汇伦医药"）发生产品销售、检测技术服务等日常关联交易事项。 根 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-026 贵阳新天药业股份有限公司 （1）现场会议时间：2025年5月19日（星期一）下午15:30开始。 （2）网络投票时间：2025年5月19日。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5 月19日上午9:15-9:25和9:30-11:30，下午13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为：2025年5月19日9:15-15:00。 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）第七届董事会第三十次会 议定于2025年5月19日（星期一）召开公司2024年年度股东大会。现将本次股东 大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024年年度股东大会。 2、股东大会的召集人：公司第七届董事会。公司第七届董事会第三十次会 议决议召开公司2024年年度股东大会。 3、会议召开的合法、合规性：公司第七届董事会第三十次会议审议通过《关 于 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-017 贵阳新天药业股份有限公司 第七届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 贵阳新天药业股份有限公司（以下简称"公司"）第七届监事会第二十一次 会议通知已于2025年4月13日以电子邮件等方式发出，于2025年4月23日上午 10:30在贵州省贵阳市乌当区高新北路3号7号楼公司会议室以现场表决的方式召 开。会议应到监事3名，实际出席会议并表决的监事3名，会议由监事会主席安万 学先生主持。本次会议的召开符合《公司法》等法律、行政法规、规范性文件和 《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于2024年度监事会工作报告的议案》 具体内容详见公司指定信息披露媒体巨潮资讯网（http://www.cninfo.com.cn） 同时发布的《2024 年度监事会工作报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2024 年年度股东大会审议。 2、审议通过《关于2024年度计提资产减值 ...

贵阳新天药业股份有限公司 监事会对内部控制评价报告的意见 根据《公司法》、《企业内部控制基本规范》和《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规章制度 的要求，贵阳新天药业股份有限公司（以下简称"公司"）董事会对公司 2024 年度内部控制情况进行了自我评价，并出具了《2024 年度内部控制评价报告》。 公司监事会在对内部控制体系的建设和运行情况进行了详细的调查和评估后，审 阅了公司《2024 年度内部控制评价报告》，现发表审核意见如下： 公司内部控制体系的建立对公司经营管理的各个环节起到了较好的风险防 范和控制作用，保证了经营管理的合法合规与资产安全，确保了财务报告及相关 信息的真实完整，提高了经营效率与效果，促进了公司发展战略的稳步实现；公 司内部控制的自我评价报告全面、真实、客观地反映了公司内部控制制度的建设 及运行情况。报告期内，公司及相关人员不存在被相关监管机构处罚的情形。 公司董事会出具的《2024 年度内部控制评价报告》内容真实、准确，客观 地反映了公司内部控制体系的建设和执行的情况，体现了公司组织架构完善，制 度健全，公司相关内部控制制度完善、 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 贵阳新天药业股份有限公司（以下简称"公司"）第七届董事会第三十次会 议通知已于2025年4月13日以电子邮件等方式发出，会议于2025年4月23日上午 9:00在上海市徐汇区东安路562号22楼（近龙华中路，绿地缤纷城）以现场结合 通讯表决的方式召开。会议应到董事9名，实际出席会议并表决的董事9名（其中 出席现场会议表决的董事有王光平先生、王文意先生、季维嘉女士、官峰先生、 张捷女士共5人，董事董大伦先生、王金华先生、何忠磊先生、高立金先生共4 人以视频等通讯方式出席会议）。会议由董事长董大伦先生主持，公司监事和高 级管理人员列席会议。本次会议的召开符合《公司法》等法律、行政法规、规范 性文件和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于 2024 年度总经理工作报告的议案》 2024 年，公司经营管理层在董事会的带领下，切实履行各项职责，贯彻落 实股东大会、董事会的各项决议，勤勉尽责地开展各项工作，在持续深化市场营 销体系改革、提升公司研发能力、升级品牌营销战略， ...

贵阳新天药业股份有限公司 关于2024年度利润分配预案的公告 证券代码：002873 证券简称：新天药业 公告编号：2025-022 二、2024 年度利润分配预案的基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）本次利润分配预案的基本内容 特别提示： 1、根据《公司法》有关规定，贵阳新天药业股份有限公司（以下简称"公 司"）已回购的股份不享有利润分配权。本次利润分配预案为：拟以未来实施利 润分配方案时股权登记日的总股本（不含公司回购专户中的股份）为基数，向全 体股东每 10 股派发现金红利人民币 0.60 元（含税），不送红股，不以资本公积 转增股本。 2、公司于 2025 年 4 月 23 日召开的第七届董事会第三十次会议、第七届监 事会第二十一次会议已审议通过了《关于 2024 年度利润分配预案的议案》，该 议案尚需提交公司 2024 年年度股东大会审议。 3、在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配金额不变的原则，相应调整分配总额，具体分配总额以实际分派金额为准。 一、审议程序 公司于 2025 年 4 月 2 ...

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 上海新天智药生物技术有限公司 | 7776.37 | 32.57 | 不变 | | 张全槐 | 997.35 | 4.18 | 不变 | | 上海国盛资本管理有限公司-上海国盛海通股权投资基金 | | | | | 合伙企业(有限合伙) | 242.35 | 1.01 | 不变 | | 贵阳开元生物资源开发有限公司 | 166.97 | 0.70 | 不变 | | 王金华 | 154.93 | 0.65 | -2.82 | | 上海银叶投资有限公司-银叶-攻玉主题精选2期私募证券 投资基金 | 150.85 | 0.63 | 不变 | | 马晟 | 107.50 | 0.45 | 新进 | | 博道远航混合A | 104.91 | 0.44 | 新进 | | 颜之华 | 98.90 | 0.41 | 14.34 | | 蔡强 | 96.23 | 0.40 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 王 ...

Financial Performance - The company's operating revenue for 2024 was ¥857,548,653.35, a decrease of 10.11% compared to ¥953,981,876.69 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥52,322,877.14, down 35.30% from ¥80,871,062.07 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥35,131,052.77, a decline of 53.16% from ¥75,009,549.39 in 2023[18]. - The basic earnings per share for 2024 was ¥0.2375, a decrease of 31.93% compared to ¥0.3489 in 2023[18]. - The total assets at the end of 2024 were ¥1,950,501,320.49, an increase of 2.02% from ¥1,911,798,773.73 at the end of 2023[18]. - The net assets attributable to shareholders increased by 7.31% to ¥1,194,715,847.70 at the end of 2024 from ¥1,113,331,133.10 at the end of 2023[18]. - The net cash flow from operating activities for 2024 was ¥88,130,214.33, an increase of 13.30% from ¥77,782,320.97 in 2023[18]. - The weighted average return on equity for 2024 was 5.02%, down from 7.01% in 2023[18]. Revenue Breakdown - The company's total revenue for the first quarter was ¥177,321,934.57, with a net profit attributable to shareholders of ¥15,571,957.55[22]. - In the second quarter, revenue increased to ¥264,377,493.59, while net profit decreased slightly to ¥14,767,492.94[22]. - The third quarter saw a revenue of ¥219,145,829.65 and a significant increase in net profit to ¥30,660,310.74[22]. - The fourth quarter reported a revenue of ¥196,703,395.54, but a net loss of ¥8,676,884.09 was recorded[22]. - The main business revenue was ¥856,873,728.73, accounting for 99.92% of total revenue, also down by 10.11% year-on-year[68]. - The gynecology product category generated ¥613,469,860.20, which is 71.54% of total revenue, reflecting a decline of 9.21% from the previous year[68]. Research and Development - The company has established a comprehensive R&D platform covering the entire lifecycle of drug development, including new drug discovery, quality standards research, and clinical evaluation[34]. - The company is focusing on the development of innovative traditional Chinese medicine (TCM) drugs, particularly in gynecology and urology, with a robust pipeline of 1.1 class innovative drugs[62]. - The innovative drug pipeline includes treatments for bacterial vaginosis and chronic prostatitis, with ongoing projects aimed at prostate hyperplasia and related inflammation[62][63]. - The company has 29 invention patents, 2 utility model patents, and 13 design patents, demonstrating a strong focus on innovation in traditional Chinese medicine[46]. - The company is actively developing over 300 traditional Chinese medicine formula granules, covering areas such as gynecology, pediatrics, and geriatrics[46]. - The company emphasizes a "production-generation, reserve-generation, development-generation" strategy for research and development in traditional Chinese medicine[45]. Market Strategy and Positioning - The company aims to enhance its market presence in women's health, urology, and chronic diseases, while also expanding into elderly and pediatric medications[35]. - The flagship product, He Yan® Kun Tai Capsule, ranks first in both hospital and retail sectors for menopausal traditional Chinese medicine in 2023, indicating strong market performance[41]. - The product Ning Pi Tai® Ning Pi Tai Capsule ranks fifth in the hospital sector for urinary tract infection traditional Chinese medicine in 2023, showcasing its competitive position[42]. - The product Ku Li Shu® Ku Shen Gel ranks third in the hospital sector for gynecological inflammation external use traditional Chinese medicine in 2023, reflecting its effectiveness and market acceptance[43]. - The company aims to become a leading brand in its niche market within the next 3-5 years, focusing on the strategy of "big single product + strong brand"[54]. - The marketing model emphasizes professional market promotion, which has improved product recognition and trust among clinical doctors and patients[52]. Operational Efficiency - The company has completed the automation and intelligent upgrades of multiple production lines, establishing a smart capacity supply guarantee center, which will significantly enhance production efficiency and cost control[51]. - The company has implemented a centralized procurement system to manage inventory and ensure the availability of necessary materials for production[48]. - The company has received 11 national new drug certificates and 31 drug approval numbers, indicating a robust pipeline of products[46]. - The company adheres to GMP standards in its production processes, ensuring high-quality manufacturing[49]. - The company has initiated a reform of its marketing system since 2022, focusing on cost reduction and efficiency improvement, which has led to a decrease in sales expense ratio[68]. Risk Management - The management discussed potential risks and countermeasures in the future development outlook section of the report[3]. - The company faces industry policy risks, including potential price declines due to healthcare reforms, and plans to mitigate this by expanding sales channels and enhancing product quality[106]. - The company acknowledges product development risks, including long cycles and high costs, and is focused on project management and protecting core technologies[107]. - The company is addressing accounts receivable risks by strengthening management and monitoring processes to ensure timely collections[107]. - Environmental risks are acknowledged due to production processes, and the company is committed to maintaining compliance with regulations while managing costs[108]. Corporate Governance - The board of directors consists of 9 members, including 3 non-independent directors, complying with legal and regulatory requirements[115]. - The supervisory board remains unchanged with 3 members, including 1 employee representative, fulfilling its supervisory role effectively[116]. - The company has established a complete business system and operates independently from its controlling shareholder, ensuring no competition with related parties[114]. - The company has a remuneration decision-making process involving the shareholders' meeting and the board of directors, with a dedicated compensation and assessment committee[145]. - The company has established an internal control system to ensure compliance and effective operation[121]. Shareholder Engagement - The company emphasizes shareholder returns through dividends and active investor relations management, aiming to enhance its investment value[105]. - The company plans to distribute a cash dividend of ¥0.60 per 10 shares to shareholders[3]. - The annual shareholders' meeting had a participation rate of 42.90% on May 13, 2024[129]. - The first temporary shareholders' meeting in 2024 had a participation rate of 37.89% on September 20, 2024[129]. - The second temporary shareholders' meeting in 2024 had a participation rate of 35.11% on December 23, 2024[129]. Environmental Responsibility - The company adheres to national and local environmental protection laws and regulations in its operations[175]. - The company has successfully implemented environmental protection measures, with all facilities operating continuously and meeting discharge standards[180]. - The company has received environmental protection administrative approvals for its projects, ensuring compliance with industry standards[179]. - The company has established emergency response plans for environmental incidents, with annual training and drills conducted[185]. - The company has a comprehensive waste management strategy, including the proper disposal of hazardous waste according to environmental regulations[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 193,151,214.98, representing an increase of 8.93% compared to CNY 177,321,934.57 in the same period last year[5]. - Net profit attributable to shareholders decreased by 73.11% to CNY 4,187,454.45 from CNY 15,571,957.55 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 81.21% to CNY 2,765,376.35 compared to CNY 14,715,210.15 in the previous year[5]. - Basic earnings per share dropped by 74.44% to CNY 0.0172 from CNY 0.0673 in the same period last year[5]. - Total operating revenue for the current period reached ¥193,151,214.98, an increase of 8.3% compared to ¥177,321,934.57 in the previous period[17]. - Net profit for the current period was ¥4,187,454.45, a decrease of 73.1% compared to ¥15,571,957.55 in the previous period[18]. - Basic earnings per share decreased to ¥0.0172 from ¥0.0673, reflecting a significant decline in profitability[18]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 22.43% to CNY 15,986,135.81 from CNY 20,608,457.90 year-on-year[5]. - Cash flow from operating activities generated a net amount of ¥15,986,135.81, down 22.5% from ¥20,608,457.90 in the previous period[20]. - The company reported a net cash outflow from financing activities of CNY -22,937,787.36, a significant increase in outflow compared to CNY -4,751,467.96 in the previous year[9]. - The company experienced a net cash outflow from financing activities of ¥22,937,787.36, worsening from an outflow of ¥4,751,467.96 in the previous period[22]. - The company's cash and cash equivalents decreased from CNY 118,164,427.88 to CNY 99,758,021.83, a decline of approximately 15.5%[14]. - Cash and cash equivalents at the end of the period totaled ¥99,758,021.83, a decrease from ¥140,605,931.76 at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,497,598.80, a decrease of 1.69% from CNY 1,950,501,320.49 at the end of the previous year[5]. - Total current assets decreased from CNY 616,807,046.83 to CNY 588,809,486.84, a decline of about 4.5%[14]. - Total liabilities decreased from CNY 755,785,472.79 to CNY 718,594,296.65, a reduction of approximately 4.9%[16]. - The total assets decreased from CNY 1,950,501,320.49 to CNY 1,917,497,598.80, a decline of approximately 1.7%[14]. - The company's retained earnings increased from CNY 563,396,301.30 to CNY 567,583,755.75, reflecting a growth of about 0.4%[16]. - The total equity attributable to the parent company increased slightly from CNY 1,194,715,847.70 to CNY 1,198,903,302.15, an increase of approximately 0.3%[16]. Borrowings and Financing - Short-term borrowings decreased by 60.44% to CNY 121,134,180.55 from CNY 306,242,291.69, reflecting a repayment of bank loans[9]. - Long-term borrowings increased significantly from CNY 221,400,000.00 to CNY 391,880,000.00, an increase of about 77%[16]. - The company's short-term borrowings decreased significantly from CNY 306,242,291.69 to CNY 121,134,180.55, a reduction of about 60.5%[16]. Research and Development - Research and development expenses increased by 74.89% to CNY 9,153,093.49 from CNY 5,233,578.17 year-on-year, indicating a significant investment in innovation[9]. - Research and development expenses increased to ¥9,153,093.49, up 74.5% from ¥5,233,578.17, indicating a focus on innovation[17]. Inventory and Receivables - Accounts receivable increased from CNY 308,443,933.77 to CNY 319,507,090.39, reflecting a growth of about 3.4%[14]. - Inventory decreased from CNY 145,478,159.62 to CNY 129,515,012.25, a reduction of approximately 11%[14]. - Sales expenses rose to ¥84,366,283.27, an increase of 9.6% compared to ¥77,379,857.99 in the previous period[17].